GlassScriptPhysician profile
Charles L Bryan
NPI 1063499614
$10,153.14
in general payments reported to CMS, 2019-2025
44 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $708 · 2021: $1,469 · 2022: $1,145 · 2023: $2,345 · 2024: $1,404 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,472 · Travel and Lodging: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,471.51 |
| Travel and Lodging | $1,144.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,424.84 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $1,323.14 | 2019-2025 | Nucala, Trelegy Ellipta |
| Medical Device Business Services, INC. | $1,190.88 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $1,161.43 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Jazz Pharmaceuticals INC. | $720.08 | 2019-2025 | |
| Electromed, INC. | $537.89 | 2019-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $497.53 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $497.33 | 2019-2025 | Opsumit, Uptravi |
| Insmed, INC. | $374.86 | 2020-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $364.73 | 2019-2025 | |
| Grifols USA, LLC | $201.27 | 2020-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $192.89 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $170.22 | 2023-2025 | Lumryz |
| Verona Pharma, INC. | $149.17 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $134.51 | 2019-2023 | Yupelri |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $132.55 | 2020-2025 | Glassia |
| Alexion Pharmaceuticals, INC. | $127.28 | 2019-2022 | |
| Amgen INC. | $93.05 | 2022-2025 | Tezspire |
| Baxter Healthcare | $83.30 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Lilly USA, LLC | $73.85 | 2025 | Zepbound, Mounjaro |
| Philips North America LLC | $66.98 | 2019-2025 | Vest Therapy Und |
| Vifor Pharma, INC. | $66.78 | 2024-2025 | Zemaira |
| Olympus America INC. | $55.62 | 2020 | |
| Pulmonx Corporation | $47.61 | 2022-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Allergan, INC. | $44.98 | 2019 | |
| Gilead Sciences, INC. | $41.60 | 2019 | |
| Ani Pharmaceuticals, INC. | $40.61 | 2022-2024 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $36.74 | 2022-2023 | |
| Fisher & Paykel Healthcare INC | $32.65 | 2020-2021 | |
| Inogen, INC. | $32.13 | 2022-2024 | |
| Vapotherm INC | $24.37 | 2022 | |
| Merck Sharp & Dohme LLC | $21.48 | 2024 | Winrevair |
| Alnylam Pharmaceuticals INC. | $19.64 | 2023 | Oxlumo |
| Csl Behring | $18.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.23 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.68 | 2021 | |
| Siemens Medical Solutions USA, INC. | $15.70 | 2023 | Cerianna |
| Shire North American Group INC | $15.68 | 2019 | |
| United Therapeutics Corporation | $15.34 | 2022 | |
| Atricure, INC. | $14.67 | 2023 | |
| Abbvie INC. | $13.63 | 2023 | Avycaz |
| Sunovion Pharmaceuticals INC. | $11.94 | 2020 | |
| Harmony Biosciences LLC | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.